chloroquine and derivatives - versus placebo - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.80 [0.52, 1.24]< 10%1 study (1/-)84.0 %some concernnot evaluable moderatecrucial-
deaths 0.81 [0.59, 1.12]< 10%5 studies (5/-)90.0 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 0.80 [0.52, 1.24]< 10%1 study (1/-)84.0 %some concernnot evaluable moderatecrucial-
clinical deterioration 1.80 [0.62, 5.21]< 10%1 study (1/-)13.9 %some concernnot evaluable moderateimportant-
clinical improvement 1.02 [0.73, 1.42]> 10%1 study (1/-)54.6 %lownot evaluable highimportant-
clinical improvement (14-day) 1.02 [0.73, 1.42]> 10%1 study (1/-)54.6 %lownot evaluable highimportant-
clinical improvement (28-day) 0.97 [0.69, 1.37]> 10%1 study (1/-)43.2 %lownot evaluable highimportant-
clinical improvement (7-day) 1.16 [0.84, 1.61]> 10%1 study (1/-)81.4 %lownot evaluable highimportant-
clinical improvement (time to event analysis only) 1.01 [0.79, 1.28]> 10%2 studies (2/-)52.7 %some concernnot evaluable moderateimportant-
death or ventilation 1.04 [0.64, 1.67]< 10%3 studies (3/-)43.9 %some concernnot evaluable moderateimportant-
hospital discharge 1.04 [0.75, 1.44]> 10%2 studies (2/-)58.8 %some concernnot evaluable moderateimportant-
off oxygenation 0.98 [0.64, 1.51]> 10%1 study (1/-)46.4 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 1.26 [0.56, 2.84]< 10%1 study (1/-)28.7 %lownot evaluable highimportant-
adverse events 1.33 [0.88, 2.01]< 10%2 studies (2/-)8.5 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.